Additionally, three other BCRP inhibitors (amiodarone, erlotinib and rifampicin) exhibited significantly increased RORs for rhabdomyolysis, whereas six inhibitors (cyclosporine, dabigatran, felodipine, nilotinib, ritonavir and sildenafil) showed elevated RORs that did not reach statistical significance.
← all excerpts
Using Pharmacovigilance Data for Signal Detection of Drug Interactions for Rosuvastatin.
1
—
—